Landogrozumab clinical trials
Also written LY2495655.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How each study uses landogrozumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- LY2495655
- 5
Studies by the year they started
5 studies that test it; most in 2011 (3)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2011 | 3 |
| 2012 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses landogrozumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Phase 2 Study of LY2495655 in Participants With Pancreatic CancerCompletedPhase 2Eli Lilly and CompanyNCT01505530Written as LY2495655
- A Study of LY2495655 in Healthy SubjectsCompletedPhase 1Eli Lilly and CompanyNCT01341470Written as LY2495655
- A Dose-Escalation Study in Participants With Advanced CancerCompletedPhase 1Eli Lilly and CompanyNCT01524224Written as LY2495655
- A Study of LY2495655 in Older Participants Undergoing Elective Total Hip ReplacementCompletedPhase 2Eli Lilly and CompanyNCT01369511Written as LY2495655
- A Study in Older Participants Who Have Fallen and Have Muscle WeaknessCompletedPhase 2Eli Lilly and CompanyNCT01604408Written as LY2495655
Codes
What other systems call landogrozumab · ClinicalTrials.gg INT000455
- MeSH (NLM) C000607476landogrozumabOne source NLM
- UNII (FDA) B1792M902RLANDOGROZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q25326697LandogrozumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C99640LandogrozumabOne source FDA
- DrugBank DB11862One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000607476 | landogrozumab | One source NLM |
| UNII (FDA) | B1792M902R | LANDOGROZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q25326697 | Landogrozumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C99640 | Landogrozumab | One source FDA |
| DrugBank | DB11862 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.